These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 30025822

  • 1. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
    Bi Y, Verginadis II, Dey S, Lin L, Guo L, Zheng Y, Koumenis C.
    Gynecol Oncol; 2018 Sep; 150(3):534-544. PubMed ID: 30025822
    [Abstract] [Full Text] [Related]

  • 2. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
    Shen YT, Evans JC, Zafarana G, Allen C, Piquette-Miller M.
    Mol Pharm; 2018 Jul 02; 15(7):2742-2753. PubMed ID: 29750868
    [Abstract] [Full Text] [Related]

  • 3. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC.
    Expert Opin Investig Drugs; 2016 Jul 02; 25(5):597-611. PubMed ID: 26899229
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
    Parmar K, Kochupurakkal BS, Lazaro JB, Wang ZC, Palakurthi S, Kirschmeier PT, Yang C, Sambel LA, Färkkilä A, Reznichenko E, Reavis HD, Dunn CE, Zou L, Do KT, Konstantinopoulos PA, Matulonis UA, Liu JF, D'Andrea AD, Shapiro GI.
    Clin Cancer Res; 2019 Oct 15; 25(20):6127-6140. PubMed ID: 31409614
    [Abstract] [Full Text] [Related]

  • 6. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D.
    Gynecol Oncol; 2014 Jun 15; 133(3):599-606. PubMed ID: 24631446
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
    Gupta VG, Hirst J, Petersen S, Roby KF, Kusch M, Zhou H, Clive ML, Jewell A, Pathak HB, Godwin AK, Wilson AJ, Crispens MA, Cybulla E, Vindigni A, Fuh KC, Khabele D.
    Gynecol Oncol; 2021 Jul 15; 162(1):163-172. PubMed ID: 33867143
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    Secord AA, Barnett JC, Ledermann JA, Peterson BL, Myers ER, Havrilesky LJ.
    Int J Gynecol Cancer; 2013 Jun 15; 23(5):846-52. PubMed ID: 23666017
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY, Kim DH, Cho BJ, Choi EJ, Lee JS, Wu HG, Chie EK, Kim IA.
    BMC Cancer; 2015 Mar 03; 15():89. PubMed ID: 25884663
    [Abstract] [Full Text] [Related]

  • 14. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
    Miller RE, Ledermann JA.
    Clin Adv Hematol Oncol; 2016 Aug 03; 14(8):619-27. PubMed ID: 27487106
    [Abstract] [Full Text] [Related]

  • 15. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
    van de Ven M, van der Burg E, van der Gulden H, Klarenbeek S, Bouwman P, Jonkers J.
    J Pathol; 2017 Mar 03; 241(4):511-521. PubMed ID: 27943283
    [Abstract] [Full Text] [Related]

  • 16. Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer.
    Parsels LA, Engelke CG, Parsels J, Flanagan SA, Zhang Q, Tanska D, Wahl DR, Canman CE, Lawrence TS, Morgan MA.
    Mol Cancer Ther; 2021 Feb 03; 20(2):263-273. PubMed ID: 33268569
    [Abstract] [Full Text] [Related]

  • 17. Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer.
    Eetezadi S, Evans JC, Shen YT, De Souza R, Piquette-Miller M, Allen C.
    Mol Pharm; 2018 Feb 05; 15(2):472-485. PubMed ID: 29283581
    [Abstract] [Full Text] [Related]

  • 18. [Abnormalities of DNA repair and gynecological cancers].
    Auguste A, Leary A.
    Bull Cancer; 2017 Nov 05; 104(11):971-980. PubMed ID: 29054544
    [Abstract] [Full Text] [Related]

  • 19. DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumors.
    Wang T, Kyle AH, Baker JHE, Liu NA, Banáth JP, Teymori S, Minchinton AI.
    DNA Repair (Amst); 2024 Jul 05; 139():103689. PubMed ID: 38749239
    [Abstract] [Full Text] [Related]

  • 20. Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib.
    Zhang Q, Xu Y, Zhang Z, Li J, Xia Q, Chen Y.
    Gene; 2021 Feb 15; 769():145243. PubMed ID: 33069804
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.